The telmisartan Programme of Research tO show Telmisartan End-organ proteCTION (PROTECTION) programme

Journal of Hypertension, Supplement

Volumn 21, Issue 6, 2003, Pages

  Weber, Michael ^a  

^a NONE   (United States)

Author keywords

Angiotensin II; Angiotensin II receptor blockers; Endothelial dysfunction; Hypertension; Left ventricular hypertrophy; Nephropathy; Telmisartan; Type 2 diabetes

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; LOSARTAN; RAMIPRIL; TELMISARTAN; VALSARTAN;

BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; BLOOD VESSEL INJURY; CONFERENCE PAPER; DRUG EFFECT; DRUG MECHANISM; HEALTH PROGRAM; HEART INJURY; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; HIGH RISK POPULATION; HYPERTENSION; KIDNEY DISEASE; KIDNEY INJURY; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PRIORITY JOURNAL; STROKE; SYSTOLIC HYPERTENSION;

EID: 0041332950     PISSN: 09521178     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200307006-00007     Document Type: Conference Paper

References (63)

1. Unger T. Blood pressure lowering and the renin-angiotensin system blockade. J Hypertens 2003; 21 (suppl 6):S3-S7.
2. McInnes GT. Clinical potential: angiotensin converting enzyme inhibitor or angiotensin II antagonist? J Hypertens 2001; 19(suppl 1):S61-S67.
3. Mervaala E, Muller DN, Schmidt F, Park JK, Gross V, Bader M, et al. Blood pressure-independent effects in rats with human renin and angiotensinogen genes. Hypertension 2000; 35:587-594.
4. Wienen W, Entzeroth M. Effects on binding characteristics and renal function of the novel, non-peptide angiotensin II antagonist BIBR 277 in the rat. J Hypertens 1994; 12:119-128.
5. 1 receptor antagonist telmisartan in patients with mild to moderate hypertension. Adv Ther 1998; 15:206-217.
6. Stangier J, Su C-APF, van Heiningen PNM, Meinicke T, van Lier JJ, de Bruin H, et al. Inhibitory effect of telmisartan on the blood pressure response to angiotensin II challenge. J Cardiovasc Pharmacol 2001; 38:672-685.
7. Smith DHG, Neutel JM, Morgenstern P. Once-daily telmisartan compared with enalapril in the treatment of hypertension. Adv Ther 1998; 15:229-240.
8. Littlejohn T, Mroczek W, Marbury T, VanderMaelen CP, Dubiel RF. A prospective, randomized, open-label trial comparing telmisartan 80 mg and valsartan 80 mg in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring. Can J Cardiol 2000; 16:1123-1132.
9. Mallion JM, Siché JP, Lacourcière Y, the Telmisartan Blood Pressure Monitoring Group. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. J Hum Hypertens 1999; 13:657-664.
10. Mancia G, Cattaneo BM, Omboni S, Grassi G. Clinical benefits of a consistent reduction in blood pressure. J Hypertens 1998; 16(suppl 6):S35-S39.
11. Cutler JA. High blood pressure and end-organ damage. J Hypertens 1996; 14(suppl):S3-S6.
12. Guidelines Subcommittee. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999; 17:151-183.
13. Thürmann PA, Kenedi P, Schmidt A, Harder S, Rietbrock N. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation 1999; 98:2037-2042.
14. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869.
15. Dahlöf B. Left ventricular hypertrophy and angiotensin II antagonists. Am J Hypertens 2001; 14:174-182.
16. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860.
17. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345:870-878.
18. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115:41-46.
19. Wheeldon NM, Viberti GC, the MARVAL Trial. Microalbuminuria reduction with valsartan. Am J Hypertens 2001; 14:A2.
20. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003.
21. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993; 118:577-581.
22. Nelson RG, Bennett PH, Beck GJ, Tan M, Knowler WC, Mitch WE, et al. Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. Diabetic Renal Disease Study Group. N Engl J Med 1996; 335:1636-1642.
23. Parving HH. Initiation and progression of diabetic nephropathy. N Engl J Med 1996; 335:1682-1683.
24. Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999; 353:617-622.
25. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355:253-259.
26. Cleland SJ, Petrie JR, Small M, Elliott HL, Connell JM. Insulin action is associated with endothelial function in hypertension and type 2 diabetes. Hypertension 2000; 35:507-511.
27. Taylor AA. Pathophysiology of hypertension and endothelial dysfunction in patients with diabetes mellitus. Endocrinol Metab Clin North Am 2001; 30:983-997.
28. Hansen HP, Lund SS, Rossing P, Tarnow L, Nielsen FS, Jensen T, et al. Preventing diabetic nephropathy: an audit. Scand J Clin Lab Invest 2001; 61:471-477.
29. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106:672-678.
30. Fogo AB. The role of angiotensin II and plasminogen activator inhibitor-1 in progressive glomerulosclerosis. Am J Kidney Dis 2000; 35:179-188.
31. Anderson S. Mechanisms of injury in progressive renal disease. Exp Nephrol 1996; 4(suppl 1):34-40.
32. Unger T. The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol 2002; 89(suppl 2A):3A-10A.
33. Garthwaite J, Garthwaite G, Palmer RM, Moncada S. NMDA receptor activation induces nitric oxide synthesis from arginine in rat brain slices. Eur J Pharmacol 1989; 172:413-416.
34. Moncada S, Palmer RM, Higgs EA. The discovery of nitric oxide as the endogenous nitrovasodilator. Hypertension 1988; 12:365-372.
35. Aeschbacher BC, Hutter D, Fuhrer J, Weidmann P, Delacretaz E, Allemann Y. Diastolic dysfunction precedes myocardial hypertrophy in the development of hypertension. Am J Hypertens 2001; 14:106-113.
36. Kannel WB. Potency of vascular risk factors as the basis for antihypertensive therapy. Eur Heart J 1992; 13(suppl G):34-42.
37. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998; 97:48-54.
38. Dahlöf B. Effect of angiotensin II blockade on cardiac hypertrophy and remodelling: a review. J Hum Hypertens 1995; 9(suppl 5):S37-S44.
39. Fyhrquist F, Metsarinne K, Tikkanen I. Role of angiotensin II in blood pressure regulation and in the pathophysiology of cardiovascular disorders. J Hum Hypertens 1995; 9(suppl 5):S19-S24.
40. Zhu YC, Zhu YZ, Gohlke P, Stauss HM, Unger T. Effects of angiotensin-converting enzyme inhibition and angiotensin II AT1 receptor antagonism on cardiac parameters in left ventricular hypertrophy. Am J Cardiol 1997; 80(suppl A):110A-117A.
41. Zhu YZ, Zhu Y-C, Li J, Schäfer H, Schmidt W, Yao T, et al. Effects of losartan on haemodynamic parameters and angiotensin receptor mRNA levels in rat heart after myocardial infarction. J Renin Angiotensin Aldosterone Syst 2000; 1:257-262.
42. Baker KM, Aceto JF. Angiotensin II stimulation of protein synthesis and cell growth in chick heart cells. Am J Physiol 1990; 259:H610-H618.
43. Benfield P, Clissold SP, Brogden RN. Metoprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischaemic heart disease and related cardiovascular disorders. Drugs 1986; 31:376-429.
44. Galzerane D, Cerciello A, Tammaro P, Latte S, Saetta G, Mallardo M, et al. Freehand three-dimensional echocardiographic assessment of efficacy of telmisartan on left ventricular mass in hypertensive patients: a multicentre study. J Hypertens 2002; 20(suppl 4):S161 [P0675].
45. Bottini PB, Carr AA, Prisant LM, Flickinger FW, Allison JD, Gottdiener JS. Magnetic resonance imaging compared to echocardiography to assess left ventricular mass in the hypertensive patient. Am J Hypertens 1995; 8:221-228.
46. Mancia G, Zanchetti A, Agabiti-Rosei E, Benemio G, De Cesaris R, Fogari R, et al. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. Circulation 1997; 95:1464-1470.
47. van den Hoogen PC, Feskens EJ, Nagelkerke NJ, Menotti A, Nissinen A, Kromhout D, et al. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. N Engl J Med 2000; 342:1-8.
48. Vasan RS, Larson MG, Leip EP, Evans JC, O'Donnell CJ, Kannel WB, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001; 345:1291-1297.
49. White W. Relevance of blood pressure variation in the circadian onset of cardiovascular events. J Hypertens 2003; 21(suppl 6):S9-S15.
50. Mallion JM, Baguet J-P, Siche J-P, Tremel F, De Gaudemaris R. Clinical value of ambulatory blood pressure monitoring. J Hypertens 1999; 17:585-595.
51. Morgan DB, Davidson C. Hypokalaemia and diuretics: an analysis of publications. BMJ 1980; 280:905-908.
52. Andrén L, Weiner L, Svensson A, Hansson L. Enalapril with either a 'very low' or 'low' dose of hydrochlorothiazide is equally effective in essential hypertension. A double-blind trial in 100 hypertensive patients. J Hypertens 1983; 1(suppl 2):384-386.
53. Skoularigis J, Strugo V, Chopamba A, Setekge S, Sareli P. Low dose hydrochlorothiazide (12.5 to 25 mg daily) as monotherapy in black patients with mild to moderate hypertension. Assessment by ambulatory blood pressure monitoring. Am J Hypertens 1995; 8:1046-1050.
54. Weir MR. When antihypertensive monotherapy fails: fixed-dose combination therapy. South Med J 2000; 93:548-556.
55. Burnier M, Maillard M. The comparative pharmacology of angiotensin II receptor antagonists. Blood Press 2001; 10(suppl 1):6-11.
56. Pi-Sunyer FX. The obesity epidemic: pathophysiology and consequences of obesity. Obes Res 2002; 10(suppl 2):97S-104S.
57. American Diabetes Association. American Diabetes Association: clinical practice recommendations 2002. Diabetes Care 2002; 25(suppl 1):S1-S147.
58. Cushman WC. The clinical significance of systolic hypertension. Am J Hypertens 1998; 11(11 Pt 2):182S-185S.
59. Kannel WB, Dawber TR, McGee DL. Perspectives on systolic hypertension. The Framingham study. Circulation 1980; 61:1179-1182.
60. Staessen JA, Gasowski J, Wang JG, Thijs L, Den Hond E, Boissel JP, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000; 355:865-872.
61. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 1991; 265:3255-3264.
62. The HOPE Study Investigators. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Can J Cardiol 1996; 12:127-137.
63. Gerstein HC. Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE. Diabetes Metab Res Rev 2002; 18(suppl 3):S82-S85.